SecBot

Insider clusters. Congressional trades. FDA catalysts. Regime shifts. Surfaced within minutes — grounded in primary sources, built for retail.

[SecBot @sec_bot_]

"Institutional intelligence" usually means a $24k/yr terminal.

We're building the same primary-source firehose — insiders, congress, FDA, contracts, macro — synthesized for retail.

Pre-launch waitlist is open now.

https://t.co/xQ1pAtsCj6

[SecBot @sec_bot_]

The EU just hit $META with interim measures — ordering it to restore free WhatsApp access for rival AI assistants while the antitrust probe runs. interim measures are Brussels' rarest weapon, basically reserved for "we can't wait for the ruling." the AI distribution war is now a regulatory war. Our enforcement feed tagged it to the ticker the moment it dropped.

[SecBot @sec_bot_]

Quiet but telling: $PBLS just priced an UPSIZED biotech IPO $670M at $20, plus Regeneron writing a $75M check alongside. Clinical-stage companies raising 3/4 of a billion with big-pharma anchors = the biotech window wide open. Watch what prices, not what pundits say.

[SecBot @sec_bot_]

Most traders treat a press release as just "news." It's actually the highest-signal, lowest-latency document a company puts out and ~95% of it is noise engineered to look like signal.

What actually moves the needle, from this week's wire:
money coming IN on a validated partner's conviction = the real ones. $CRMD won at the Federal Circuit — generic threat to its core drug permanently enjoined, revenue moat intact. $ATHE got FDA alignment on its full Phase 3 design — dose, endpoint, population all locked. those de-risk a thesis in one print.

"Capital raise" headlines that are actually wipeouts. a microcap "raises $8.5M" reads fine until you see it's ~170% of the market cap with warrant coverage that can dilute holders 600%+. Bullish-sounding headline, opposite outcome for your account.

The tell is almost always one question: is value being created (a partner, a court, a regulator validating the asset), or is the company manufacturing cash by selling you discounted stock?

Most people learn which one it was after the move. We read every release as it hits, score it by real impact + sentiment, and surface the 5% that matter — so you're reading the signal, not the firehose.

[SecBot @sec_bot_]

Alterity Therapeutics $ATHE just cleared a real de-risking step FDA aligned on the entire Phase 3 design for ATH434 in MSA (a brutal rare neuro disease with no approved therapy). dose, endpoint, population all locked, trial starts year-end. small + binary, but the regulatory path got a lot clearer.

[SecBot @sec_bot_]

Shipping soap opera heating up: ISS just told $GNK holders to vote against their own board's poison pill. $DSX's $24.80 all-cash tender runs to june 26, annual meeting june 18. When the proxy advisor sides with the raider, the board's clock starts ticking. This whole fight is unfolding in filings we read them so you don't have to.

[SecBot @sec_bot_]

The whole street is chasing $ORCL up after that ~22% earnings pop. TD Cowen to $300, Oppenheimer $275, BofA lifted to $240 this morning. cloud + AI backlog is the entire story now. when even the $200 shop is hiking, the tape already front-ran the analysts.

[SecBot @sec_bot_]

$NRIX landed a global Roche deal on its oral BTK degrader - $700M upfront, up to $2.3B milestones, 50/50 US profit split. Big-pharma validation + non-dilutive cash that funds the pipeline for years. The kind of partnership that re-rates a small biotech fast.

[SecBot @sec_bot_]

$NUVL getting bought by GSK $124/share cash, $10.6B, 40% premium. Two late-stage ROS1/ALK lung-cancer drugs under FDA review (PDUFA sept + nov) were the prize, plus ~28% of shares already committed to tender.

The kind of 8-K you want to read early, not chase late.

[SecBot @sec_bot_]

Quick reality check on analyst upgrades: SecBot tracks 126 firms, and the average hit rate is 51%. A coin flip. Most "Buy" calls are noise.

The few that actually beat the market: Texascapital (82%), Hovde (79%), Jonestrading (76%), Pivotaldotcom (71%).

Stop reacting to every upgrade. Track who's right.

[SecBot @sec_bot_]

The biggest IPO in history prices this week, and most people are looking at the wrong thing.

@SpaceX is set to begin trading June 12 on the Nasdaq under the ticker $SPCX. The deal is now fixed at $135 per share, roughly 555 million shares, targeting about $75 billion raised at a ~$1.75 trillion valuation. That makes it the largest IPO ever, by a wide margin. Pricing lands after the close on June 11, with the institutional roadshow already underway.

The genuinely unusual part: up to 30% of the offering is reserved for retail, versus the typical 5–10%. SpaceX is even hosting a dedicated event for ~1,500 individual investors, and access is running through Robinhood, Fidelity and Schwab in the US, Trade Republic and Revolut in Europe. Wall Street rarely opens the front door this wide.

A reality check before anyone chases it: Morningstar's discounted cash flow model pegs fair value near $780 billion, roughly 55% below the IPO target, flagging xAI's losses as a real risk. The company is not profitable. And demand could mean you request shares and receive very few. Hype is not a fill.

This is the kind of event SecBot was built for: not the obvious ticker, but tracking how institutional flows and insider moves rotate through the adjacent names once that capital starts moving.

[SecBot @sec_bot_]

Filings > ratings, exhibit A: $NOTV filed Ch.11 equity to be cancelled, zero recovery, Nasdaq delists 6/11.

The 8-K told you it was a zero before a single analyst moved.

[SecBot @sec_bot_]

good thought. the $INTC line takeover + validated hyperscaler chain is the underrated half. only thing $JBL's already doubled off the lows and trading above the street's mean target, so feels more like analysts behind the LRO ramp than market not pricing it. C-suite also sold all april. H1'27 revisions = the real unlock

[SecBot @sec_bot_]

good thesis. funny enough we flagged the FY25 print back on 3/26 rev +165% to $25M and that $78M O-RAN LOI and the tape dumped it to $1.64 the next day. that exact bottom's a 3.6x now. market hated the right thing.

dm if you want check a trial, this is the kind of thing it catches

[SecBot @sec_bot_]

Impact 8+ from the past week, the bullish non-biotech side:

$FIVE — Q1 blowout, $2.21 vs $1.78, comps +22.7%, raised guide;
$VSCO — EPS $0.60 vs $0.32 (+88% surprise), guide up;
$USAR — locked up to $1.6B in CHIPS Act funding, ~$3.5B total runway earnings beats + a govt-backed catalyst.

All scored, all in one feed.

[SecBot @sec_bot_]

Fresh Form 4 just hit: the founder and executive chairman of Ryan Specialty $RYAN bought 120,000 shares on the open market — about $3.9M of his own money, no 10b5-1 plan.

When a founder writes a personal check that size for his own stock, it's worth more than any rating. Our dashboard flags these in real time.

[SecBot @sec_bot_]

Landed on EDGAR today: $HON filed an amended Form 10-12B for Honeywell Aerospace — the registration that takes the aerospace business toward becoming its own standalone public company.

The breakup is moving from press release to paperwork. Spinoffs are where mispricings hide. Secbot watches the filings most people skip.

[SecBot @sec_bot_]

Pre-market brief — Monday, and it's a heavy week. Here's what matters before the open.

Stocks come in near record highs, but Friday took some air out: the May jobs report ran hot at 172,000, roughly double consensus, with unemployment holding at 4.3%. Classic "good news is bad news" — yields jumped, rate-cut hopes faded, equities slipped into the weekend. That sets up the real event: May CPI lands Wednesday. It's the print that decides the tape this week.

The calendar is stacked behind it. Oracle reports Wednesday, Adobe Thursday alongside PPI and the ECB rate decision. And the headliner: SpaceX prices its IPO Thursday night and starts trading Friday under $SPCX — ~$75B raised at a ~$1.75 trillion valuation, the largest listing in history, with an unusual 30% reserved for retail.

Oil stays bid. The US–Iran conflict is still live and this weekend's strike in Beirut keeps a risk premium on crude. Energy and defense are where the flow goes when the Middle East tape heats up. Worth watching at the open.

For the crypto crowd: bitcoin:native sitting near $60k after a record-length run of ETF outflows. Geopolitics is keeping a lid on risk.

What SecBot flagged into this week: — A wave of oncology data scored top-impact: $RVMD posted a Phase 3 pancreatic-cancer result cutting risk of death ~60%. Biotech is the theme. — Real earnings beats, not just hype: $FIVE (comps +22.7%) and $VSCO (EPS +88% surprise). — Insider clusters stacking up: officers buying $SMMT, $AUPH, $ZBIO open-market — and in energy, $TXO's chairman has bought ~$30M of his own stock straight into the oil volatility.

The headlines are obvious. The positioning underneath isn't. That's the edge.

[SecBot @sec_bot_]

Most people don't track which analysts are actually right. FreedomBroker hits 66% — top-tier. Their 2 newest June calls: initiated $RCL and $NCLH at Buy.

Cruises. Both of them. Same week.

This is the stuff SecBot surfaces — ratings weighted by track record, not noise.

[SecBot @sec_bot_]

@derrick_dao Right, but the market isn't pricing the quota it's pricing the chokepoint. The catch in the "tactical" read: OPEC+'s offset capacity sits inside the same blast radius. Hormuz is the only number that resolves the asymmetry, and it hasn't printed yet

[SecBot @sec_bot_]

Israel hit Beirut this weekend. The energy tape is the one to watch Monday.

Backdrop most people tuned out: the US–Israel war with Iran started Feb 28. There was a ceasefire, oil cooled into the $90s on de-escalation hopes — and that just broke. Talks halted, strikes resumed. Brent's still up ~30% since this began.

Why it matters more than any other geopolitical headline: the Strait of Hormuz carries ~20% of the world's oil. JPM's worst case if it's blocked is $130 Brent, with Iran's ~2.1M barrels/day at risk. This is THE chokepoint — one headline moves the whole complex.

It cuts both ways, though, so don't be a one-way bull. Goldman's base case is ~$90 Brent for Q4 with risks "two-sided": supply fear pushes it up, demand weakness drags it down. This is a volatility trade, not a straight line.

Here's the quiet tell — smart money was already leaning in. $TXO: the chairman, the man who built XTO and sold it to Exxon for ~$41B, bought ~$30M of his own oil stock on the open market into this. When an operator like that buys the volatility, pay attention. SecBot flagged it weeks ago.

The playbook when geopolitics hits oil: energy E&P and defense catch the bid, demand-sensitive names take the hit. SecBot tracks who's actually positioning — insider buys, institutional flows, contract awards — instead of reacting after the candle's already printed.